Imsight

What Imsight does

Imsight is a Hong Kong-founded AI medical imaging software company, established in 2016, that develops deep learning systems to assist radiologists and pathologists in disease detection and treatment planning. The company operates through a Shenzhen headquarters serving mainland China, a Hong Kong subsidiary (Imsight Technology) for overseas markets, and engineering offices in Chengdu and Guiyang. Its core technology is built around convolutional neural networks trained on a proprietary database of 260,000 medical imaging scans, with deployments integrated into hospital PACS and RIS workflows.

Imsight's product portfolio includes four commercially deployed diagnostic systems (DR-Sight for chest X-ray analysis of 19 pulmonary lesions with triage and structured reporting; Lung-Sight for CT lung nodule detection with Lung-RAD/CNNC reporting; Cervical-Sight for liquid-based cytology cervical cancer screening handling up to 2,000 cases daily; and Rib-Sight for rib fracture detection) plus research-stage products (Cervix-Pilot for radiotherapy planning, BoneAge-Sight, and Breast-Sight for lymph node metastasis detection) and DeepCT for intracranial hemorrhage detection. DeepCT was among the first AI diagnostic software products registered with Hong Kong's MDCO in September 2021, and Lung-Sight obtained CFDA Class II certification in 2019.

The company sells primarily through direct enterprise sales to hospitals and imaging centers using a quote-based annual subscription model, supplemented by professional implementation services and custom algorithm development. It has named deployments at Prince of Wales Hospital, Hong Kong Advanced Imaging, iRad Medical Diagnostic Centre, The Specialists, and Shenzhen No. 3 People's Hospital, with 30+ hospitals across Hong Kong and the Greater Bay Area and an additional 100+ hospital footprint in Japan. Distribution channels include direct sales, PACS integration partnerships (Evolucare, OphtAI, Deep01), and a Microsoft cloud infrastructure partnership, with no publicly disclosed pricing or revenue.

Name

Imsight

Legal name

Imsight

Website

https://imsightmed.hk

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

Imsight is a Hong Kong-based AI medical imaging software company founded in 2016 that builds deep learning diagnostic systems for hospitals and imaging centers. Its portfolio spans chest X-ray, CT lung nodule, cervical cytology, rib fracture, intracranial hemorrhage, and radiotherapy planning applications, deployed across 30+ hospitals in Hong Kong and the Greater Bay Area and 100+ hospitals in Japan.

Ownership category

akta.pro rank

Product category

AI Medical Imaging Software

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industries

Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ), AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

Keywords

• AI medical imaging
• Radiology diagnostics software
• Deep learning healthcare
• Computer-aided detection
• Medical image analysis

Headquarters

HQ city

Hong Kong

HQ country

Hong Kong SAR China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

1. AI Medical Imaging Diagnostic Systems: Imsight generates revenue through licensing and deployment of AI-powered medical imaging diagnostic software solutions to hospitals, medical imaging centers, and healthcare institutions. The company provides AI systems that analyze X-rays, CT scans, and pathology images to assist radiologists and pathologists in disease detection and diagnosis.
2. Implementation and Technical Support Services: Professional services including system implementation, integration with existing hospital PACS/RIS systems, configuration, and ongoing technical support. The company offers plug-and-play implementation solutions.
3. Custom Algorithm Development: Co-creation services for developing custom AI algorithms and solutions tailored to specific therapeutic areas or institutional requirements, including multi-center research and clinical trials.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Imsight develops and sells AI-powered medical imaging diagnostic software that analyzes X-ray, CT, and histopathology images to assist radiologists and pathologists in detecting diseases. The product suite includes DR-Sight (chest X-ray), Lung-Sight (CT lung nodule analysis), Cervical-Sight (cervical cancer screening), Rib-Sight (rib fracture detection), and DeepCT (intracranial hemorrhage detection), all built on convolutional neural networks trained on a 260,000-scan database.

Product overview

Imsight is an AI-powered medical imaging software company offering a suite of diagnostic products that analyze medical images to assist radiologists and pathologists. The core product line includes four commercially deployed AI systems: DR-Sight (chest X-ray AI detecting 19 pulmonary lesions with triage and structured reporting), Lung-Sight (CT-based lung nodule analysis with Lung-RAD/CNNC structured reporting and follow-up tracking), Cervical-Sight (deep learning cytology screening for cervical cancer on liquid-based slides, handling up to 2,000 cases/day), and Rib-Sight (AI detection of rib fractures on X-ray and CT). The research pipeline includes Cervix-Pilot (AI-assisted radiotherapy planning for cervical cancer), BoneAge-Sight (automated bone age assessment from hand X-rays), and Breast-Sight (histopathology-based lymph node metastasis detection for breast cancer staging). DeepCT (intracranial hemorrhage detection) was listed with Hong Kong MDCO in 2021. All products leverage a proprietary database of 260,000 scans and use deep learning (convolutional neural networks) for automated disease identification and structured report generation, integrated with PACS workflows.

Differentiator

Problem solved

Functional benefit

Brands

• DR-Sight: Chest X-ray AI-assisted diagnosis system that can identify 19 pulmonary lesions (tuberculosis, pneumothorax, pleural effusion) and generate structured reports.
• Lung-Sight
• Cervical-Sight
• Rib-Sight
• DeepCT
• Breast-Sight
• BoneAge-Sight
• Cervix-Pilot

Quantifiable outcome

• Sensitivity >85% for lung nodule detection
• +5 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability5 records

Feature7 records

Partnerships

Six partnerships are on record, tiered core and minor.

• EvolucarecoreTechnology or IntegrationPACS integration partnership where Evolucare embeds Imsight's AI technology into their medical imaging solutions. Evolucare's products include Medical Imaging Asia, WebHospital, and integrated web platforms that incorporate Imsight's AI diagnostic capabilities.
• MicrosoftcoreTechnology or IntegrationCloud infrastructure partnership providing the foundation for Imsight's AI solutions. The collaboration enables data processing, AI computation, and global research collaboration supported by Microsoft's cloud platform.
• Hong Kong University - Department of PathologycoreStrategic or Co-development PartnerAcademic research partnership for cervical cytology types and differential diagnosis studies. Professor Pan Qinjing from HKU visited Imsight for academic seminar on pathology.
• Hong Kong Software Industry Association (HKSIA)minorGTM or Marketing PartnerIndustry association that invited Imsight as exhibitor at the 22nd China Hi-Tech Fair, representing Hong Kong software industry.
• Hong Kong Hospital AuthoritycoreStrategic or Co-development PartnerStrategic partnership where Imsight was invited to participate in Hospital Authority Lunch & Learn webinar to explore AI applications in smart hospitals. Dr. Clare Lai presented on AI solutions for hospital workflows.
• Nature JournalminorGTM or Marketing PartnerMedia partnership for editorial coverage. Nature published an interview with Imsight CEO Chen Hao on the future of medical AI.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Lunit: Korean AI medical imaging company specializing in chest X-ray and mammography AI (Lunit INSIGHT). Comparable as Asia-based medical imaging AI vendor with similar product focus on radiology and similar regulatory pathway across Asian markets including Japan.
• Aidoc: Israeli AI medical imaging company offering AI-powered workflow and triage solutions for CT and X-ray, deployed in US and European hospitals. Comparable as a focused medical imaging AI vendor with multi-product radiology suite and FDA-cleared products.
• Zebra Medical Vision (Nanox): AI medical imaging company (acquired by Nanox) developing AI algorithms for radiology reading across multiple modalities and clinical conditions. Comparable as a multi-product AI imaging vendor with similar breadth of diagnostic use cases.
• Infervision (推想科技): Beijing-based AI medical imaging company offering similar radiology AI products including chest CT, DR, and stroke detection. Directly comparable as a Chinese AI imaging vendor targeting hospitals with deep learning diagnostic tools.
• Yitu Technology (依图科技): Chinese AI company with medical imaging division developing diagnostic AI for radiology and pathology. Comparable as a multi-product AI medical imaging vendor operating in Chinese hospital systems with similar regulatory and market dynamics as Imsight.
• United Imaging Intelligence: AI division of United Imaging Healthcare developing AI applications for medical imaging including CT and MR analysis. Comparable as China-based medical imaging AI vendor with imaging equipment manufacturer backing.

Emerging players

• Deep01: Taiwan-based AI medical imaging company focused on intracranial hemorrhage and stroke detection, partner of Imsight in the PACS integration ecosystem. Comparable as Asia-based focused medical imaging AI vendor targeting hospital radiology workflows.

Broad incumbents

• Siemens Healthineers (AI-Rad Companion): Global medical technology company with AI-Rad Companion and other AI-powered imaging applications. Comparable as broad incumbent in medical imaging AI with overlapping radiology use cases, though operates as part of larger imaging equipment portfolio.
• Hologic (Genius AI): Medical technology company with Genius AI for mammography and cervical cytology screening. Comparable for Imsight's Breast-Sight and Cervical-Sight products as a larger incumbent in women's health AI imaging.
• GE Healthcare (Edison AI Platform): Global medical imaging equipment manufacturer with extensive Edison AI platform offering AI applications for radiology workflows. Comparable as provider of AI imaging capabilities to hospitals, though GE is broader portfolio including imaging equipment itself.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imsight